Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

By L. Silverman, E. Demakos, B. Peterson, A. Kornblith, J. C. Holland, R. Odchimar-Reissig, R. Stone, D. Nelson, B. Powell, C. Decastro and 4 more. Journal of Clinical Oncology, 2002

1,823 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/05de71e7be38fff7e7aab0867bdbdfea829f32ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. S. Baylin
2. Peter A. Jones
3. J. Herman
4. Jean-Pierre Issa
5. F. Lyko
6. N. Sharpless
7. R. DePinho
8. Manel Esteller

In Hematology

1. Peter A. Jones
2. S. Baylin
3. G. Sauvageau
4. Martin Sauvageau

In Oncology

1. Jean-Pierre Issa
2. Peter A. Jones
3. S. Baylin
4. R. DePinho
5. Ralph Weissleder
6. M. Pittet

Citations in the corpus

• Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “Decitabine (DAC) and its analog azacitidine (AZA), two major DNA demethylating agents (Jones and Taylor, 1980), have recently emerged as potent therapies for the preleukemic hematological disease myelodysplastic syndrome (MDS), and for established leukemias (Blum et al., 2007; Cashen et al., 2010; I”
• Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine (2008, background): “After substantial refinements in their clinical dosing schedules, both azacytidine and decitabine have now shown significant clinical benefits in the treatment of myelodysplastic syndrome (MDS), a preleukemic bone marrow disorder.(3,4) As a consequence, these drugs have now received FDA approval for”
• CpG island methylator phenotype in cancer (2004, background): “, and a specific DNA methylation inhibitor (5-azacytidine) has now been approved for use as an anti-cancer agent in the US”
• Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development (2006, positive): “, but its remarkable single-agent activity in myelodysplasia was only finally confirmed in a randomized trial in 2002 (Ref”
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, methodology): “A crossover trial from the Cancer and Leukemia Group B (CALBG) included 191 patients with MDS classified according to FAB criteria who were randomly assigned to standard supportive care or subcutaneous azacitidine 75 mg/m(2) per day for 7 days every 28 days for 4 cycles.(192) Significantly higher co”
• Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non Small Cell Lung Cancer (2011, background): “Low-dose azacitidine or decitabine regimens have led to successful treatment of myelodysplastic syndrome (5, 14, 29, 30) with improved survival (31).”
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, neutral): “Median number of courses (range) 5 (1-18) 8 (1-17) 9 (1-15)”
• DNMT3A Mutations in Acute Myeloid Leukemia (2010, neutral): “NPM1 27/216 (13) 24/37 (65) 13/25 (52) 37/62 (60) <0.”